{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"16"},{"groupId":"OG002","value":"6"}],"units":"Participants"}],"description":"Number of subjects with a complete response (CR), partial response (PR) or stable disease (SD). CR is defined as disappearance of all tumor lesions selected for measurement. PR is defined as at least 30% decrease in the sum of all tumor lesions selected for measurement. Stable disease is defined as neither sufficient tumor shrinkage to qualify for PR nor sufficient tumor increase to qualify for progressive disease (PD) which is defined as at least 20% increase the sum of the all tumor lesions selected for measurement.","groups":[{"description":"0.015 mg/kg/dose of ALT-801","id":"OG000","title":"ALT-801 0.015 mg/kg/Dose"},{"description":"0.040 mg/kg/dose of ALT-801","id":"OG001","title":"ALT-801 0.040 mg/kg/Dose"},{"description":"0.080 mg/kg/dose of ALT-801","id":"OG002","title":"ALT-801 0.080 mg/kg/Dose"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"24 months","title":"Clinical Antitumor Response to ALT-801","type":"SECONDARY","unitOfMeasure":"participants"}